LT3988656T - Su nukleosoma sąveikaujančių baltymų domenų panaudojimas tikslinės genomo modifikacijos pagerinimui - Google Patents

Su nukleosoma sąveikaujančių baltymų domenų panaudojimas tikslinės genomo modifikacijos pagerinimui

Info

Publication number
LT3988656T
LT3988656T LTEP21193940.0T LT21193940T LT3988656T LT 3988656 T LT3988656 T LT 3988656T LT 21193940 T LT21193940 T LT 21193940T LT 3988656 T LT3988656 T LT 3988656T
Authority
LT
Lithuania
Prior art keywords
nucleosoma
interacting protein
protein domains
genome modification
targeted genome
Prior art date
Application number
LTEP21193940.0T
Other languages
English (en)
Inventor
Fuqiang Chen
Xiao DING
Yongmei FENG
Gregory D Davis
Original Assignee
Sigma-Aldrich Co. Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Aldrich Co. Llc filed Critical Sigma-Aldrich Co. Llc
Publication of LT3988656T publication Critical patent/LT3988656T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/80Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTEP21193940.0T 2017-07-11 2018-07-11 Su nukleosoma sąveikaujančių baltymų domenų panaudojimas tikslinės genomo modifikacijos pagerinimui LT3988656T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762531222P 2017-07-11 2017-07-11

Publications (1)

Publication Number Publication Date
LT3988656T true LT3988656T (lt) 2024-11-11

Family

ID=62916578

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP18182999.5T LT3428274T (lt) 2017-07-11 2018-07-11 Su nukleosoma sąveikaujančių baltymų domenų panaudojimas tikslinės genomo modifikacijos pagerinimui
LTEP21193940.0T LT3988656T (lt) 2017-07-11 2018-07-11 Su nukleosoma sąveikaujančių baltymų domenų panaudojimas tikslinės genomo modifikacijos pagerinimui

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP18182999.5T LT3428274T (lt) 2017-07-11 2018-07-11 Su nukleosoma sąveikaujančių baltymų domenų panaudojimas tikslinės genomo modifikacijos pagerinimui

Country Status (17)

Country Link
US (3) US10604752B2 (lt)
EP (2) EP3428274B1 (lt)
JP (3) JP6994560B2 (lt)
KR (3) KR20240046316A (lt)
CN (1) CN111183226A (lt)
AU (3) AU2018299995B2 (lt)
CA (1) CA3066790C (lt)
DK (2) DK3428274T3 (lt)
ES (2) ES2901629T3 (lt)
FI (1) FI3988656T3 (lt)
GB (3) GB2567917B (lt)
IL (2) IL309801B2 (lt)
LT (2) LT3428274T (lt)
PL (2) PL3988656T3 (lt)
PT (2) PT3428274T (lt)
SG (1) SG11201911864PA (lt)
WO (1) WO2019014230A1 (lt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP3443081A4 (en) 2016-04-13 2019-10-30 Duke University CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
KR20240046316A (ko) 2017-07-11 2024-04-08 시그마-알드리치 컴퍼니., 엘엘씨 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
US12509492B2 (en) 2018-01-19 2025-12-30 Duke University Genome engineering with CRISPR-Cas systems in eukaryotes
JP7109547B2 (ja) * 2018-02-15 2022-07-29 シグマ-アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー 真核ゲノム修飾のための操作されたCas9システム
GB2587970B (en) 2018-04-19 2023-02-08 Univ California Compositions and methods for gene editing
WO2020036653A2 (en) * 2018-04-25 2020-02-20 The Regents Of The University Of California Improved method for homology directed repair in cells
BR112020024736A2 (pt) 2018-06-04 2021-03-23 University Of Copenhagen endonucleases cpf1 mutantes
AU2019291918B2 (en) 2018-06-29 2025-06-12 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
WO2020187272A1 (zh) * 2019-03-19 2020-09-24 上海邦耀生物科技有限公司 一种用于基因治疗的融合蛋白及其应用
CN111718420B (zh) * 2019-03-19 2021-09-14 华东师范大学 一种用于基因治疗的融合蛋白及其应用
CN111718418B (zh) * 2019-03-19 2021-08-27 华东师范大学 一种增强基因编辑的融合蛋白及其应用
SG11202111982UA (en) * 2019-05-13 2021-11-29 Emd Millipore Corp Synthetic self-replicating rna vectors encoding crispr proteins and uses thereof
AU2020345830A1 (en) * 2019-09-09 2022-03-24 Beam Therapeutics Inc. Novel CRISPR enzymes, methods, systems and uses thereof
WO2021224506A1 (en) * 2020-05-08 2021-11-11 Universitat Pompeu Fabra Crispr-cas homology directed repair enhancer
CA3182672A1 (en) * 2020-05-08 2021-11-11 Duke University Chromatin remodelers to enhance targeted gene activation
WO2022059928A1 (ko) * 2020-09-21 2022-03-24 고려대학교 산학협력단 신규의 개량된 염기 편집 또는 교정용 융합단백질 및 이의 용도
EP4230737A4 (en) * 2020-09-21 2024-07-24 Korea University Research and Business Foundation NOVEL IMPROVED BASIC EDITING OR REVISION FUSION PROTEIN AND USE THEREOF
EP4230738A4 (en) * 2020-09-24 2024-11-20 Korea University Research and Business Foundation Prime editing-based gene editing composition with enhanced editing efficiency and use thereof
MX2023005150A (es) * 2020-11-06 2023-05-26 Pairwise Plants Services Inc Composiciones y metodos para el reemplazo de alelos con adn codificado por arn.
CN114507689B (zh) * 2022-01-27 2024-01-16 山东大学 一种提高真核生物基因编辑效率的方法及其应用
CN115716880A (zh) * 2022-12-07 2023-02-28 云舟生物科技(广州)股份有限公司 一种核定位荧光蛋白及其应用
CN115948465B (zh) * 2022-12-16 2025-09-19 中国农业科学院北京畜牧兽医研究所 猪hat1基因修饰系统及应用
WO2026097018A1 (en) * 2024-11-04 2026-05-07 Intellia Therapeutics, Inc. Polypeptides, polynucleotides, compositions, and methods for genome editing involving chromatin remodelers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005010A (es) 2001-11-26 2005-04-08 Advanced Cell Tech Inc METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS.
US20050003403A1 (en) 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
EP2834357B1 (en) 2012-04-04 2017-12-27 Life Technologies Corporation Tal-effector assembly platform, customized services, kits and assays
JP2015527889A (ja) * 2012-07-25 2015-09-24 ザ ブロード インスティテュート, インコーポレイテッド 誘導可能なdna結合タンパク質およびゲノム撹乱ツール、ならびにそれらの適用
EP3135765A1 (en) 2012-12-06 2017-03-01 Sigma-Aldrich Co. LLC Crispr-based genome modification and regulation
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US10378027B2 (en) * 2013-03-15 2019-08-13 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
WO2015048577A2 (en) * 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
US10570418B2 (en) * 2014-09-02 2020-02-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification
WO2016049251A1 (en) * 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US10190106B2 (en) 2014-12-22 2019-01-29 Univesity Of Massachusetts Cas9-DNA targeting unit chimeras
AU2015370435A1 (en) 2014-12-24 2017-06-15 Dana-Farber Cancer Institute, Inc. Systems and methods for genome modification and regulation
ES2886599T3 (es) * 2015-06-17 2021-12-20 Poseida Therapeutics Inc Composiciones y métodos para dirigir proteínas a loci específicos en el genoma
EP3313445A1 (en) 2015-06-24 2018-05-02 Sigma Aldrich Co. LLC Cell cycle dependent genome regulation and modification
CN107922953B (zh) 2015-08-20 2022-03-04 应用干细胞有限公司 提高基因编辑效率的核酸酶
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
KR20240046316A (ko) 2017-07-11 2024-04-08 시그마-알드리치 컴퍼니., 엘엘씨 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용

Also Published As

Publication number Publication date
GB2593814A (en) 2021-10-06
LT3428274T (lt) 2021-11-25
AU2022200851A1 (en) 2022-03-03
EP3428274B1 (en) 2021-10-13
GB202114520D0 (en) 2021-11-24
JP6994560B2 (ja) 2022-02-21
EP3988656A1 (en) 2022-04-27
US20210024916A1 (en) 2021-01-28
EP3988656B9 (en) 2024-11-27
ES2901629T3 (es) 2022-03-23
FI3988656T3 (fi) 2024-10-29
GB2598847B (en) 2022-06-01
IL271197B1 (en) 2024-02-01
GB2598847A (en) 2022-03-16
GB2567917B (en) 2021-05-12
KR20240046316A (ko) 2024-04-08
GB2593814B (en) 2022-01-05
IL309801A (en) 2024-02-01
PL3428274T3 (pl) 2022-01-03
JP2020530287A (ja) 2020-10-22
EP3428274A1 (en) 2019-01-16
AU2022200851B2 (en) 2023-12-14
AU2018299995A1 (en) 2020-01-02
US20190017042A1 (en) 2019-01-17
KR102523217B1 (ko) 2023-04-20
JP7469285B2 (ja) 2024-04-16
CA3066790A1 (en) 2019-01-17
US12065642B2 (en) 2024-08-20
WO2019014230A1 (en) 2019-01-17
KR102655021B1 (ko) 2024-04-04
IL309801B1 (en) 2024-08-01
CA3066790C (en) 2023-07-18
US10604752B2 (en) 2020-03-31
DK3988656T3 (da) 2024-11-11
US12221606B2 (en) 2025-02-11
AU2021245148B2 (en) 2024-01-04
CN111183226A (zh) 2020-05-19
GB2567917A (en) 2019-05-01
KR20230053732A (ko) 2023-04-21
ES2997490T3 (en) 2025-02-17
PT3428274T (pt) 2021-11-05
GB201811358D0 (en) 2018-08-29
PT3988656T (pt) 2024-11-07
IL271197A (en) 2020-01-30
AU2021245148A1 (en) 2021-11-04
JP2024096783A (ja) 2024-07-17
KR20200021529A (ko) 2020-02-28
US20200208135A1 (en) 2020-07-02
IL309801B2 (en) 2024-12-01
EP3988656B1 (en) 2024-09-18
JP2022046532A (ja) 2022-03-23
PL3988656T3 (pl) 2024-12-16
DK3428274T3 (da) 2021-11-15
IL271197B2 (en) 2024-06-01
SG11201911864PA (en) 2020-01-30
GB202103935D0 (en) 2021-05-05
AU2018299995B2 (en) 2021-10-28
BR112019028261A2 (pt) 2020-07-14

Similar Documents

Publication Publication Date Title
IL295358A (en) Using programmable dna binding proteins to enhance targeted genome modification
DK3428274T3 (da) Anvendelse af nukleosominteragerende proteindomæner til forbedring af målrettet genommodifikation
IL286888A (en) Use of pridopidine to treat depression or anxiety
IL290809A (en) Tau-protein targeting protacs and associated methods of use
IL282077B (en) Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics
EP3695666C0 (en) DETECTION OF DRIVING ACTIONS THAT MITIGATE RISK
IL256079A (en) Humanized and affinity matured antibodies to fcrh5 and methods of use
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
EP3349581A4 (en) HEPATITIS B CORE PROTEIN MODULATORS
PT3250610T (pt) Anticorpos de fcrn e métodos de utilização dos mesmos
MA47611A (fr) Compositionset méthodes de transduction tumorale
ME03335B (me) Konstrukti uspa2 proteina i njihove upotrebe
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
MA43134A (fr) Compositions et méthodes de transduction tumorale
LT3368044T (lt) Kepenų steatozės, susijusios su oligo-ovuliacija, gydymas
PL3661510T3 (pl) Sposoby leczenia zmian zachowania
EP3595688A4 (en) GENE THERAPY TO TREAT FAMILY HYPERCHOLESTEROLEMIA
IL270817A (en) Use of glutamine synthetase for treating hyperammonemia
DK3500586T3 (da) Kontinuerlig fremgangsmåde til at reducere heterogenitet af terapeutisk protein
EP3691174C0 (en) CONFIGURATION OF TWO-LEVEL MOBILITY REFERENCE SIGNALS
EP3590033A4 (en) CONTENT PROVISION
EP3430893C0 (de) Anordnung zur verhinderung der passage von tieren
EP3573609A4 (en) USE OF SENICAPOC FOR THE TREATMENT OF A CEREBRAL VASCULAR ACCIDENT
EP3384786A4 (en) USE OF ENZYME-MODIFIED ISOQUERCITRIN
EP3445367A4 (en) INHIBITORS OF HEPATITIS C VIRUS